Zura Bio Limited Class A Ordinary Shares (ZURA) - Total Assets
Based on the latest financial reports, Zura Bio Limited Class A Ordinary Shares (ZURA) holds total assets worth $143.94 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Zura Bio Limited Class A Ordinary Shares for net asset value and shareholders' equity analysis.
Zura Bio Limited Class A Ordinary Shares - Total Assets Trend (2021–2024)
This chart illustrates how Zura Bio Limited Class A Ordinary Shares's total assets have evolved over time, based on quarterly financial data.
Zura Bio Limited Class A Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
Zura Bio Limited Class A Ordinary Shares's total assets of $143.94 Million consist of 99.6% current assets and 0.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Zura Bio Limited Class A Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZURA market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zura Bio Limited Class A Ordinary Shares's current assets represent 99.6% of total assets in 2024, an increase from 0.8% in 2021.
- Cash Position: Cash and equivalents constituted 98.3% of total assets in 2024, up from 0.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Zura Bio Limited Class A Ordinary Shares Competitors by Total Assets
Key competitors of Zura Bio Limited Class A Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Zura Bio Limited Class A Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.58 | 10.36 | 0.13 |
| Quick Ratio | 5.58 | 10.36 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.80 Million | $170.73 Million | $-166.96K |
Zura Bio Limited Class A Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Zura Bio Limited Class A Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 1.36 |
| Asset Growth Rate (YoY) | 78.0% |
| Total Assets | $179.53 Million |
| Market Capitalization | $243.84 Million USD |
Valuation Analysis
Above Book Valuation: The market values Zura Bio Limited Class A Ordinary Shares's assets above their book value (1.36x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Zura Bio Limited Class A Ordinary Shares's assets grew by 78.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zura Bio Limited Class A Ordinary Shares (2021–2024)
The table below shows the annual total assets of Zura Bio Limited Class A Ordinary Shares from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $179.53 Million | +78.03% |
| 2023-12-31 | $100.84 Million | +1816.44% |
| 2022-12-31 | $5.26 Million | -96.26% |
| 2021-12-31 | $140.55 Million | -- |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more